AASLD Practice Guidelines

You have full text access to this OnlineOpen article

Diagnosis, management, and treatment of hepatitis C: An update†‡§

  1. Marc G. Ghany1,
  2. Doris B. Strader2,
  3. David L. Thomas3,
  4. Leonard B. Seeff4,¶,*

Article first published online: 2 DEC 2008

DOI: 10.1002/hep.22759

Issue

Hepatology

Hepatology

Volume 49, Issue 4, pages 1335–1374, April 2009

Additional Information

How to Cite

Ghany, M. G., Strader, D. B., Thomas, D. L. and Seeff, L. B. (2009), Diagnosis, management, and treatment of hepatitis C: An update. Hepatology, 49: 1335–1374. doi: 10.1002/hep.22759

Author Information

  1. 1

    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD

  2. 2

    Division of Gastroenterology/Hepatology, Fletcher Allen Health Care, University of Vermont College of Medicine, Burlington, VT

  3. 3

    Infectious Disease, The Johns Hopkins University School of Medicine, Baltimore MD

  4. 4

    Liver Disease Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD

  1. fax: 301-480-7926

*Liver Disease Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Building 31, Room 9A27, Bethesda, MD 20892

  1. †

    Disclaimer Statement: The views expressed in these guidelines do not necessarily represent the views of the Department of Health and Human Services, the National Institutes of Health, the National Institute of Diabetes and Digestive and Kidney Diseases, or the United States Government.

  2. ‡

    Potential conflict of interest: Drs. Marc Ghany, Leonard Seeff, and Doris Strader have no financial relationships to declare. Dr. David Thomas was on the Advisory Board of Merck, Sharpe and Dohme at the time of writing but has since resigned from this position.

  3. §

    All American Association for the Study Liver Diseases (AASLD) Practice Guidelines are updated annually. If you are viewing a Practice Guideline that is more than 12 months old, please visit www.aasld.org for an update in the material.

Publication History

  1. Issue published online: 27 MAR 2009
  2. Article first published online: 2 DEC 2008
  3. Accepted manuscript online: 2 DEC 2008 12:00AM EST
  4. Manuscript Accepted: 23 NOV 2008
  5. Manuscript Received: 21 NOV 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (444K)

References

  • 1
    Eddy D. A manual for assessing health practices and designing practice guidelines. Philadelphia. American College of Physicians 1996: 1–126.
  • 2
    American Gastroenterological Association policy statement on the use of medical practice guidelines by managed care organizations and insurance carriers. Gastroenterology 1995; 108: 925–926.
  • 3
    http://www.heart.org/presenter.jhtml?identifier=3039683 MMfAApAaa.
  • 4
    Shiffman RN, Shekelle P, Overhage JM, Slutsky J, Grimshaw J, Deshpande AM. Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization. Ann Intern Med 2003; 139: 493–498.
  • 5
    Williams R. Global challenges in liver disease. HEPATOLOGY 2006; 44: 521–526.
    Direct Link:
  • 6
    www.who.int/immunization/topics/hepatitis_c/en/.
  • 7
    Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705–714.
  • 8
    Kim WR. The burden of hepatitis C in the United States. HEPATOLOGY 2002; 36(Suppl): S30–S34.
    Direct Link:
  • 9
    Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat 2007; 14: 107–115.
    Direct Link:
  • 10
    Alter MJ, Seeff LB, Bacon BR, Thomas DL, Rigsby MO, Di Bisceglie AM. Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. Ann Intern Med 2004; 141: 715–717.
  • 11
    Alter MJ. Prevention of spread of hepatitis C. HEPATOLOGY 2002; 36(Suppl): S93–S98.
    Direct Link:
  • 12
    Wasley A, Miller JT, Finelli L. Surveillance for acute viral hepatitis — United States, 2005. MMWR Surveill Summ 2007; 56: 1–24.
  • 13
    Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996; 334: 1685–1690.
  • 14
    Goedert JJ, Chen BE, Preiss L, Aledort LM, Rosenberg PS. Reconstruction of the hepatitis C virus epidemic in the US hemophilia population, 1940-1990. Am J Epidemiol 2007; 165: 1443–1453.
  • 15
    Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep 1998; 47: 1–39.
  • 16
    Jonas MM. Children with hepatitis C. HEPATOLOGY 2002; 36(Suppl): S173–S178.
    Direct Link:
  • 17
    Mast EE, Hwang LY, Seto DS, Nolte FS, Nainan OV, Wurtzel H, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis 2005; 192: 1880–1889.
  • 18
    Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006; 55: 1–94.
  • 19
    Terrault NA. Sexual activity as a risk factor for hepatitis C. HEPATOLOGY 2002; 36(Suppl): S99–S105.
    Direct Link:
  • 20
    Puro V, Petrosillo N, Ippolito G. Risk of hepatitis C seroconversion after occupational exposures in health care workers. Italian Study Group on Occupational Risk of HIV and Other Bloodborne Infections. Am J Infect Control 1995; 23: 273–277.
  • 21
    Forns X, Martinez-Bauer E, Feliu A, Garcia-Retortillo M, Martin M, Gay E, Navasa M, Sanchez-Tapias JM, Bruguera M, Rodes J. Nosocomial transmission of HCV in the liver unit of a tertiary care center. HEPATOLOGY 2005; 41: 115–122.
    Direct Link:
  • 22
    Conte D, Fraquelli M, Prati D, Colucci A, Minola E. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. HEPATOLOGY 2000; 31: 751–755.
    Direct Link:
  • 23
    Conry-Cantilena C, VanRaden M, Gibble J, Melpolder J, Shakil AO, Viladomiu L, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996; 334: 1691–1696.
  • 24
    Mele A, Corona R, Tosti ME, Palumbo F, Moiraghi A, Novaco F, et al. Beauty treatments and risk of parenterally transmitted hepatitis: results from the hepatitis surveillance system in Italy. Scand J Infect Dis 1995; 27: 441–444.
  • 25
    Sun DX, Zhang FG, Geng YQ, Xi DS. Hepatitis C transmission by cosmetic tattooing in women. Lancet 1996; 347: 541.
  • 26
    Hwang LY, Kramer JR, Troisi C, Bull L, Grimes CZ, Lyerla R, et al. Relationship of cosmetic procedures and drug use to hepatitis C and hepatitis B virus infections in a low-risk population. HEPATOLOGY 2006; 44: 341–351.
    Direct Link:
  • 27
    Tumminelli F, Marcellin P, Rizzo S, Barbera S, Corvino G, Furia P, et al. Shaving as potential source of hepatitis C virus infection. Lancet 1995; 345: 658.
  • 28
    Mansell CJ, Locarnini SA. Epidemiology of hepatitis C in the East. Semin Liver Dis 1995; 15: 15–32.
  • 29
    Briggs ME, Baker C, Hall R, Gaziano JM, Gagnon D, Bzowej N, et al. Prevalence and risk factors for hepatitis C virus infection at an urban Veterans Administration medical center. HEPATOLOGY 2001; 34: 1200–1205.
    Direct Link:
  • 30
    Balasekaran R, Bulterys M, Jamal MM, Quinn PG, Johnston DE, Skipper B, et al. A case-control study of risk factors for sporadic hepatitis C virus infection in the southwestern United States. Am J Gastroenterol 1999; 94: 1341–1346.
    Direct Link:
  • 31
    Laumann AE, Derick AJ. Tattoos and body piercings in the United States: a national data set. J Am Acad Dermatol 2006; 55: 413–421.
  • 32
    Carroll ST, Riffenburgh RH, Roberts TA, Myhre EB. Tattoos and body piercings as indicators of adolescent risk-taking behaviors. Pediatrics 2002; 109: 1021–1027.
  • 33
    Antoszewski B, Sitek A, Jedrzejczak M, Kasielska A, Kruk-Jeromin J. Are body piercing and tattooing safe fashions? Eur J Dermatol 2006; 16: 572–575.
  • 34
    Colin C, Lanoir D, Touzet S, Meyaud-Kraemer L, Bailly F, Trepo C. Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. J Viral Hepat 2001; 8: 87–95.
    Direct Link:
  • 35
    Thio CL, Nolt KR, Astemborski J, Vlahov D, Nelson KE, Thomas DL. Screening for hepatitis C virus in human immunodeficiency virus-infected individuals. J Clin Microbiol 2000; 38: 575–577.
  • 36
    Kalantar-Zadeh K, Miller LG, Daar ES. Diagnostic discordance for hepatitis C virus infection in hemodialysis patients. Am J Kidney Dis 2005; 46: 290–300.
  • 37
    Chamot E, Hirschel B, Wintsch J, Robert CF, Gabriel V, Deglon JJ, et al. Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users. Aids 1990; 4: 1275–1277.
  • 38
    Dufour DR, Talastas M, Fernandez MD, Harris B, Strader DB, Seeff LB. Low-positive anti-hepatitis C virus enzyme immunoassay results: an important predictor of low likelihood of hepatitis C infection. Clin Chem 2003; 49: 479–486.
  • 39
    Alter MJ, Kuhnert WL, Finelli L. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003; 52: 1–13, 15; quiz CE1–4.
  • 40
    Pawlotsky JM, Lonjon I, Hezode C, Raynard B, Darthuy F, Remire J, et al. What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories? HEPATOLOGY 1998; 27: 1700–1702.
    Direct Link:
  • 41
    Stramer SL, Caglioti S, Strong DM. NAT of the United States and Canadian blood supply. Transfusion 2000; 40: 1165–1168.
    Direct Link:
  • 42
    Pawlotsky JM. Molecular diagnosis of viral hepatitis. Gastroenterology 2002; 122: 1554–1568.
  • 43
    Scott JD, Gretch DR. Molecular diagnostics of hepatitis C virus infection: a systematic review. Jama 2007; 297: 724–732.
  • 44
    Saldanha J, Lelie N, Heath A. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. WHO Collaborative Study Group. Vox Sang 1999; 76: 149–158.
    Direct Link:
  • 45
    Pawlotsky JM, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D. Standardization of hepatitis C virus RNA quantification. HEPATOLOGY 2000; 32: 654–659.
    Direct Link:
  • 46
    Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. HEPATOLOGY 2005; 42: 962–973.
    Direct Link:
  • 47
    Nainan OV, Alter MJ, Kruszon-Moran D, Gao FX, Xia G, McQuillan G, et al. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology 2006; 131: 478–484.
  • 48
    Germer JJ, Rys PN, Thorvilson JN, Persing DH. Determination of hepatitis C virus genotype by direct sequence analysis of products generated with the Amplicor HCV test. J Clin Microbiol 1999; 37: 2625–2630.
  • 49
    Kleiner DE. The liver biopsy in chronic hepatitis C: a view from the other side of the microscope. Semin Liver Dis 2005; 25: 52–64.
  • 50
    Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372–374.
  • 51
    Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. HEPATOLOGY 1994; 19: 1513–1520.
    Direct Link:
  • 52
    Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995; 19: 1409–1417.
  • 53
    Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. HEPATOLOGY 1996; 24: 289–293.
    Direct Link:
  • 54
    Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696–699.
  • 55
    Rubbia-Brandt L, Fabris P, Paganin S, Leandro G, Male PJ, Giostra E, et al. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 2004; 53: 406–412.
  • 56
    Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. HEPATOLOGY 2003; 38: 75–85.
    Direct Link:
  • 57
    Olynyk JK, Reddy KR, Di Bisceglie AM, Jeffers LJ, Parker TI, Radick JL, et al. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology 1995; 108: 1104–1109.
  • 58
    Westin J, Lagging M, Dhillon AP, Norkrans G, Romero AI, Pawlotsky JM, et al. Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. J Viral Hepat 2007; 14: 29–35.
    Direct Link:
  • 59
    Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallee M, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004; 40: 484–490.
  • 60
    Fontana RJ, Israel J, LeClair P, Banner BF, Tortorelli K, Grace N, et al. Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. HEPATOLOGY 2000; 31: 730–736.
    Direct Link:
  • 61
    Reiss G, Keeffe EB. Role of liver biopsy in the management of chronic liver disease: selective rather than routine. Rev Gastroenterol Disord 2005; 5: 195–205.
  • 62
    Crockett SD, Kaltenbach T, Keeffe EB. Do we still need a liver biopsy? Are the serum fibrosis tests ready for prime time? Clin Liver Dis 2006; 10: 513–534, viii.
  • 63
    Dienstag JL. The role of liver biopsy in chronic hepatitis C. HEPATOLOGY 2002; 36(Suppl): S152–S160.
    Direct Link:
  • 64
    Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). HEPATOLOGY 2000; 32: 477–481.
    Direct Link:
  • 65
    Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614–2618.
    Direct Link:
  • 66
    Rockey DC, Bissell DM. Noninvasive measures of liver fibrosis. HEPATOLOGY 2006; 43(Suppl): S113–S120.
    Direct Link:
  • 67
    Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: 1705–1713.
  • 68
    Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343–350.
  • 69
    Arena U, Vizzutti F, Corti G, Ambu S, Stasi C, Bresci S, et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. HEPATOLOGY 2008; 47: 380–384.
    Direct Link:
  • 70
    Sagir A, Erhardt A, Schmitt M, Haussinger D. Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. HEPATOLOGY 2008; 47: 592–595.
    Direct Link:
  • 71
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–965.
  • 72
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–982.
  • 73
    Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346–355.
  • 74
    Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000; 20: 17–35.
  • 75
    Levine RA, Sanderson SO, Ploutz-Snyder R, Murray F, Kay E, Hegarty J, et al. Assessment of fibrosis progression in untreated irish women with chronic hepatitis C contracted from immunoglobulin anti-D. Clin Gastroenterol Hepatol 2006; 4: 1271–1277.
  • 76
    Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis 2005; 9: 383–398, vi.
  • 77
    Wong JB, Koff RS. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis. Ann Intern Med 2000; 133: 665–675.
  • 78
    Martinot-Peignoux M, Boyer N, Cazals-Hatem D, Pham BN, Gervais A, Le Breton V, et al. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. HEPATOLOGY 2001; 34: 1000–1005.
    Direct Link:
  • 79
    Shiffman ML, Diago M, Tran A, Pockros P, Reindollar R, Prati D, et al. Chronic hepatitis C in patients with persistently normal alanine transaminase levels. Clin Gastroenterol Hepatol 2006; 4: 645–652.
  • 80
    Boccato S, Pistis R, Noventa F, Guido M, Benvegnu L, Alberti A. Fibrosis progression in initially mild chronic hepatitis C. J Viral Hepat 2006; 13: 297–302.
    Direct Link:
  • 81
    Persico M, Persico E, Suozzo R, Conte S, De Seta M, Coppola L, et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000; 118: 760–764.
  • 82
    Yu ML, Dai CY, Lee LP, Hou NJ, Hsieh MY, Huang JF, et al. A 24-week course of high-dose interferon-alpha plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels. Liver Int 2006; 26: 1187–1195.
    Direct Link:
  • 83
    Jacobson IM, Ahmed F, Russo MW, Lebovics E, Dieterich DT, Esposito SP, et al. Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT. Am J Gastroenterol 2004; 99: 1700–1705.
    Direct Link:
  • 84
    Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, Prati D, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127: 1724–1732.
  • 85
    Strader DB, Seeff LB. The natural history of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 1996; 8: 324–328.
  • 86
    Seeff LB, Hoofnagle JH. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. HEPATOLOGY 2002; 36(Suppl): S1–S2.
    Direct Link:
  • 87
    Seeff LB. Natural history of chronic hepatitis C. HEPATOLOGY 2002; 36(Suppl): S35–S46.
    Direct Link:
  • 88
    Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000; 132: 296–305.
  • 89
    Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish HEPATOLOGY Research Group. N Engl J Med 1999; 340: 1228–1233.
  • 90
    Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study. HEPATOLOGY 2000; 32: 91–96.
    Direct Link:
  • 91
    Wiese M, Grungreiff K, Guthoff W, Lafrenz M, Oesen U, Porst H. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany—a 25-year multicenter study. J Hepatol 2005; 43: 590–598.
  • 92
    Vogt M, Lang T, Frosner G, Klingler C, Sendl AF, Zeller A, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999; 341: 866–870.
  • 93
    Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463–1466.
  • 94
    Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, et al. The long-term pathological evolution of chronic hepatitis C. HEPATOLOGY 1996; 23: 1334–1340.
    Direct Link:
  • 95
    Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. HEPATOLOGY 1999; 30: 1054–1058.
    Direct Link:
  • 96
    Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825–832.
  • 97
    Harris DR, Gonin R, Alter HJ, Wright EC, Buskell ZJ, Hollinger FB, et al. The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. Ann Intern Med 2001; 134: 120–124.
  • 98
    Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. HEPATOLOGY 2005; 42: 5–13.
    Direct Link:
  • 99
    Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463–472.
  • 100
    Fontaine H, Nalpas B, Poulet B, Carnot F, Zylberberg H, Brechot C, et al. Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C. Hum Pathol 2001; 32: 904–909.
  • 101
    National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002—June 10-12, 2002. HEPATOLOGY 2002; 36: S3–S20.
    Direct Link:
  • 102
    Kobayashi S, Takeda T, Enomoto M, Tamori A, Kawada N, Habu D, et al. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients. Liver Int 2007; 27: 186–191.
    Direct Link:
  • 103
    Yu JW, Wang GQ, Sun LJ, Li XG, Li SC. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol 2007; 22: 832–836.
    Direct Link:
  • 104
    Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. HEPATOLOGY 2006; 43: 954–960.
    Direct Link:
  • 105
    Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. HEPATOLOGY 2003; 38: 645–652.
    Direct Link:
  • 106
    Carlsson T, Reichard O, Norkrans G, Blackberg J, Sangfelt P, Wallmark E, et al. Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response. J Viral Hepat 2005; 12: 473–480.
    Direct Link:
  • 107
    Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales FL Jr, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43: 425–433.
  • 108
    Zeuzem S, Welsch C, Herrmann E. Pharmacokinetics of peginterferons. Semin Liver Dis 2003; 23(Suppl 1): 23–28.
  • 109
    Jacobson IM, Brown RS Jr, Freilich B, Afdhal N, Kwo PY, Santoro J, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. HEPATOLOGY 2007; 46: 971–981.
    Direct Link:
  • 110
    Khuroo MS, Khuroo MS, Dahab ST. Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. Aliment Pharmacol Ther 2004; 20: 931–938.
    Direct Link:
  • 111
    Kamal SM, El Kamary SS, Shardell MD, Hashem M, Ahmed IN, Muhammadi M, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. HEPATOLOGY 2007; 46: 1732–1740.
    Direct Link:
  • 112
    Nguyen MH, Trinh HN, Garcia R, Nguyen G, Lam KD, Keeffe EB. Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin. Am J Gastroenterol 2008; 103: 1131–1135.
    Direct Link:
  • 113
    Romero-Gomez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriguez CM, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636–641.
  • 114
    Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 124–134.
  • 115
    Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44: 97–103.
  • 116
    Dalgard O, Bjoro K, Hellum KB, Myrvang B, Ritland S, Skaug K, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. HEPATOLOGY 2004; 40: 1260–1265.
    Direct Link:
  • 117
    Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 2609–2617.
  • 118
    von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129: 522–527.
  • 119
    Yu ML, Dai CY, Huang JF, Hou NJ, Lee LP, Hsieh MY, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007; 56: 553–559.
  • 120
    Buti M, Sanchez-Avila F, Lurie Y, Stalgis C, Valdes A, Martell M, et al. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. HEPATOLOGY 2002; 35: 930–936.
    Direct Link:
  • 121
    Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. HEPATOLOGY 2005; 41: 275–279.
    Direct Link:
  • 122
    Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130: 1086–1097.
  • 123
    Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. HEPATOLOGY 2007; 46: 1688–1694.
    Direct Link:
  • 124
    Sanchez-Tapias JM, Diago M, Escartin P, Enriquez J, Romero-Gomez M, Barcena R, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131: 451–460.
  • 125
    Soza A, Everhart JE, Ghany MG, Doo E, Heller T, Promrat K, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. HEPATOLOGY 2002; 36: 1273–1279.
    Direct Link:
  • 126
    Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004; 126: 1302–1311.
  • 127
    Pockros PJ, Shiffman ML, Schiff ER, Sulkowski MS, Younossi Z, Dieterich DT, et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. HEPATOLOGY 2004; 40: 1450–1458.
    Direct Link:
  • 128
    Shiffman ML, Salvatore J, Hubbard S, Price A, Sterling RK, Stravitz RT, et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. HEPATOLOGY 2007; 46: 371–379.
    Direct Link:
  • 129
    Del Rio RA, Post AB, Singer ME. Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy. HEPATOLOGY 2006; 44: 1598–1606.
    Direct Link:
  • 130
    Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. Jama 2008; 299: 914–924.
  • 131
    McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, Berg et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007; 357: 2227–2236.
  • 132
    Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 2005; 19: 105–123.
  • 133
    Raison CL, Miller AH. The neuroimmunology of stress and depression. Semin Clin Neuropsychiatry 2001; 6: 277–294.
  • 134
    Cotler SJ, Wartelle CF, Larson AM, Gretch DR, Jensen DM, Carithers RL Jr. Pretreatment symptoms and dosing regimen predict side-effects of interferon therapy for hepatitis C. J Viral Hepat 2000; 7: 211–217.
    Direct Link:
  • 135
    Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB, et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002; 26: 643–652.
  • 136
    Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. HEPATOLOGY 2002; 36: 479–497.
    Direct Link:
  • 137
    Zung WW. A Self-Rating Depression Scale. Arch Gen Psychiatry 1965; 12: 63–70.
  • 138
    Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561–571.
  • 139
    Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–389.
  • 140
    Radloff L. The CES-D Scale: a self-report depression scale for research in the general population. J Applied Psychol Measurement 1977; 1: 385–401.
  • 141
    Pradat P, Tillmann HL, Sauleda S, Braconier JH, Saracco G, Thursz M, et al. Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications. J Viral Hepat 2007; 14: 556–563.
    Direct Link:
  • 142
    Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnu L, Mazzella G, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. HEPATOLOGY 2007; 45: 579–587.
    Direct Link:
  • 143
    Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677–684.
  • 144
    Bruix J, Sherman M. Management of hepatocellular carcinoma. HEPATOLOGY 2005; 42: 1208–1236.
    Direct Link:
  • 145
    Cheruvattath R, Rosati MJ, Gautam M, Vargas HE, Rakela J, Balan V. Pegylated interferon and ribavirin failures: is retreatment an option? Dig Dis Sci 2007; 52: 732–736.
  • 146
    Cornberg M, Hadem J, Herrmann E, Schuppert F, Schmidt HH, Reiser M, et al. Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study. J Hepatol 2006; 44: 291–301.
  • 147
    Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, et al. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 2004; 25: 472–492.
  • 148
    Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359: 2429–2441.
  • 149
    Taliani G, Gemignani G, Ferrari C, Aceti A, Bartolozzi D, Blanc PL, et al. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Gastroenterology 2006; 130: 1098–1106.
  • 150
    Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126: 1015–1023; discussion 947.
  • 151
    Jacobson IM, Gonzalez SA, Ahmed F, Lebovics E, Min AD, Bodenheimer HC Jr, et al. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol 2005; 100: 2453–2462.
    Direct Link:
  • 152
    Pradat P, Alberti A, Poynard T, Esteban JI, Weiland O, Marcellin P, et al. Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. HEPATOLOGY 2002; 36: 973–977.
  • 153
    Prieto M, Olaso V, Verdu C, Cordoba J, Gisbert C, Rayon M, et al. Does the healthy hepatitis C virus carrier state really exist? An analysis using polymerase chain reaction. HEPATOLOGY 1995; 22: 413–417.
  • 154
    Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. Clin Chem 2000; 46: 2027–2049.
  • 155
    Brillanti S, Foli M, Gaiani S, Masci C, Miglioli M, Barbara L. Persistent hepatitis C viraemia without liver disease. Lancet 1993; 341: 464–465.
  • 156
    Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1–10.
  • 157
    Ahmed A, Keeffe EB. Chronic hepatitis C with normal aminotransferase levels. Gastroenterology 2004; 126: 1409–1415.
  • 158
    Nutt AK, Hassan HA, Lindsey J, Lamps LW, Raufman JP. Liver biopsy in the evaluation of patients with chronic hepatitis C who have repeatedly normal or near-normal serum ala6nine aminotransferase levels. Am J Med 2000; 109: 62–64.
  • 159
    Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol 1999; 31(Suppl 1): 9–16.
  • 160
    Puoti C, Castellacci R, Montagnese F. Hepatitis C virus carriers with persistently normal aminotransferase levels: healthy people or true patients? Dig Liver Dis 2000; 32: 634–643.
  • 161
    Puoti C, Guido M, Mangia A, Persico M, Prati D. Clinical management of HCV carriers with normal aminotransferase levels. Dig Liver Dis 2003; 35: 362–369.
  • 162
    Puoti C, Magrini A, Stati T, Rigato P, Montagnese F, Rossi P, et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. HEPATOLOGY 1997; 26: 1393–1398.
    Direct Link:
  • 163
    Arora S, O'Brien C, Zeuzem S, Shiffman ML, Diago M, Tran A, et al. Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life. J Gastroenterol Hepatol 2006; 21: 406–412.
    Direct Link:
  • 164
    Bini EJ, Mehandru S. Sustained virological response rates and health-related quality of life after interferon and ribavirin therapy in patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels. Aliment Pharmacol Ther 2006; 23: 777–785.
    Direct Link:
  • 165
    Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. HEPATOLOGY 2002; 36(Suppl): S47–S56.
    Direct Link:
  • 166
    Jhaveri R, Grant W, Kauf TL, McHutchison J. The burden of hepatitis C virus infection in children: estimated direct medical costs over a 10-year period. J Pediatr 2006; 148: 353–358.
  • 167
    Hepatitis C virus infection. American Academy of Pediatrics. Committee on Infectious Diseases. Pediatrics 1998; 101: 481–485.
  • 168
    El-Kamary SS, Serwint JR, Joffe A, Santosham M, Duggan AK. Prevalence of hepatitis C virus infection in urban children. J Pediatr 2003; 143: 54–59.
  • 169
    Donahue JG, Munoz A, Ness PM, Brown DE Jr, Yawn DH, McAllister HA Jr, et al. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 1992; 327: 369–373.
  • 170
    Kleinman S, Alter H, Busch M, Holland P, Tegtmeier G, Nelles M, et al. Increased detection of hepatitis C virus (HCV)-infected blood donors by a multiple-antigen HCV enzyme immunoassay. Transfusion 1992; 32: 805–813.
    Direct Link:
  • 171
    Bortolotti F, Resti M, Giacchino R, Crivellaro C, Zancan L, Azzari C, et al. Changing epidemiologic pattern of chronic hepatitis C virus infection in Italian children. J Pediatr 1998; 133: 378–381.
  • 172
    Puro V, Girardi E, Ippolito G, Lo Presti E, Benedetto A, Zaniratti S, et al. Prevalence of hepatitis B and C viruses and human immunodeficiency virus infections in women of reproductive age. Br J Obstet Gynaecol 1992; 99: 598–600.
    Direct Link:
  • 173
    Airoldi J, Berghella V. Hepatitis C and pregnancy. Obstet Gynecol Surv 2006; 61: 666–672.
  • 174
    Pembrey L, Newell ML, Tovo PA. The management of HCV infected pregnant women and their children European paediatric HCV network. J Hepatol 2005; 43: 515–525.
  • 175
    Marcellin P, Bernuau J, Martinot-Peignoux M, Larzul D, Xu LZ, Tran S, et al. Prevalence of hepatitis C virus infection in asymptomatic anti-HIV1 negative pregnant women and their children. Dig Dis Sci 1993; 38: 2151–2155.
  • 176
    Roudot-Thoraval F, Pawlotsky JM, Thiers V, Deforges L, Girollet PP, Guillot F, et al. Lack of mother-to-infant transmission of hepatitis C virus in human immunodeficiency virus-seronegative women: a prospective study with hepatitis C virus RNA testing. HEPATOLOGY 1993; 17: 772–777.
  • 177
    Wejstal R, Widell A, Mansson AS, Hermodsson S, Norkrans G. Mother-to-infant transmission of hepatitis C virus. Ann Intern Med 1992; 117: 887–890.
  • 178
    Lam JP, McOmish F, Burns SM, Yap PL, Mok JY, Simmonds P. Infrequent vertical transmission of hepatitis C virus. J Infect Dis 1993; 167: 572–576.
  • 179
    Manzini P, Saracco G, Cerchier A, Riva C, Musso A, Ricotti E, et al. Human immunodeficiency virus infection as risk factor for mother-to-child hepatitis C virus transmission; persistence of anti-hepatitis C virus in children is associated with the mother's anti-hepatitis C virus immunoblotting pattern. HEPATOLOGY 1995; 21: 328–232.
  • 180
    Ohto H, Terazawa S, Sasaki N, Sasaki N, Hino K, Ishiwata C, et al. Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med 1994; 330: 744–750.
  • 181
    European Paediatric Hepatitis C Virus Network. Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus. Bjog 2001; 108: 371–377.
  • 182
    Kumar RM, Shahul S. Role of breast-feeding in transmission of hepatitis C virus to infants of HCV-infected mothers. J Hepatol 1998; 29: 191–197.
  • 183
    Lin HH, Kao JH, Hsu HY, Ni YH, Chang MH, Huang SC, et al. Absence of infection in breast-fed infants born to hepatitis C virus-infected mothers. J Pediatr 1995; 126: 589–591.
  • 184
    Palomba E, Manzini P, Fiammengo P, Maderni P, Saracco G, Tovo PA. Natural history of perinatal hepatitis C virus infection. Clin Infect Dis 1996; 23: 47–50.
  • 185
    Polywka S, Pembrey L, Tovo PA, Newell ML. Accuracy of HCV-RNA PCR tests for diagnosis or exclusion of vertically acquired HCV infection. J Med Virol 2006; 78: 305–310.
    Direct Link:
  • 186
    Guido M, Rugge M, Jara P, Hierro L, Giacchino R, Larrauri J, et al. Chronic hepatitis C in children: the pathological and clinical spectrum. Gastroenterology 1998; 115: 1525–1529.
  • 187
    Yeung LT, To T, King SM, Roberts EA. Spontaneous clearance of childhood hepatitis C virus infection. J Viral Hepat 2007; 14: 797–805.
    Direct Link:
  • 188
    Camarero C, Ramos N, Moreno A, Asensio A, Mateos ML, Roldan B. Hepatitis C virus infection acquired in childhood. Eur J Pediatr 2008; 167: 219–224.
  • 189
    Hsu SC, Chang MH, Chen DS, Hsu HC, Lee CY. Non-A, non-B hepatitis in children: a clinical, histologic, and serologic study. J Med Virol 1991; 35: 1–6.
    Direct Link:
  • 190
    Bortolotti F, Vajro P, Cadrobbi P, Lepore L, Zancan L, Barbera C, et al. Cryptogenic chronic liver disease and hepatitis C virus infection in children. J Hepatol 1992; 15: 73–76.
  • 191
    Rumbo C, Fawaz RL, Emre SH, Suchy FJ, Kerkar N, Morotti RA, et al. Hepatitis C in children: a quaternary referral center perspective. J Pediatr Gastroenterol Nutr 2006; 43: 209–216.
  • 192
    D'Souza R, Glynn MJ, Ushiro-Lumb I, Feakins R, Domizio P, Mears L, et al. Prevalence of hepatitis C-related cirrhosis in elderly Asian patients infected in childhood. Clin Gastroenterol Hepatol 2005; 3: 910–917.
  • 193
    Jara P, Resti M, Hierro L, Giacchino R, Barbera C, Zancan L, et al. Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children. Clin Infect Dis 2003; 36: 275–280.
  • 194
    Goodman ZD, Makhlouf HR, Liu L, Balistreri W, Gonzalez-Peralta RP, Haber B, et al. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial. HEPATOLOGY 2008; 47: 836–843.
    Direct Link:
  • 195
    Mohan P, Colvin C, Glymph C, Chandra RR, Kleiner DE, Patel KM, et al. Clinical spectrum and histopathologic features of chronic hepatitis C infection in children. J Pediatr 2007; 150: 168–174, 174 e1.
  • 196
    Fujisawa T, Inui A, Ohkawa T, Komatsu H, Miyakawa Y, Onoue M. Response to interferon therapy in children with chronic hepatitis C. J Pediatr 1995; 127: 660–662.
  • 197
    Bortolotti F, Giacchino R, Vajro P, Barbera C, Crivellaro C, Alberti A, et al. Recombinant interferon-alfa therapy in children with chronic hepatitis C. HEPATOLOGY 1995; 22: 1623–1627.
    Direct Link:
  • 198
    Marcellini M, Kondili LA, Comparcola D, Spada E, Sartorelli MR, Palumbo M, et al. High dosage alpha-interferon for treatment of children and young adults with chronic hepatitis C disease. Pediatr Infect Dis J 1997; 16: 1049–1053.
  • 199
    Gonzalez-Peralta RP, Kelly DA, Haber B, Molleston J, Murray KF, Jonas MM, et al. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. HEPATOLOGY 2005; 42: 1010–1018.
    Direct Link:
  • 200
    Wirth S, Lang T, Gehring S, Gerner P. Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. HEPATOLOGY 2002; 36: 1280–1284.
    Direct Link:
  • 201
    Christensson B, Wiebe T, Akesson A, Widell A. Interferon-alpha and ribavirin treatment of hepatitis C in children with malignancy in remission. Clin Infect Dis 2000; 30: 585–586.
  • 202
    Wirth S, Pieper-Boustani H, Lang T, Ballauff A, Kullmer U, Gerner P, et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. HEPATOLOGY 2005; 41: 1013–1018.
    Direct Link:
  • 203
    Jara P, Hierro L, de la Vega A, Diaz C, Camarena C, Frauca E, et al. Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection. Pediatr Infect Dis J 2008; 27: 142–148.
  • 204
    Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34: 831–837.
  • 205
    Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 492–497.
  • 206
    Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853–860.
  • 207
    Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166: 1632–1641.
  • 208
    Bonacini M, Lin HJ, Hollinger FB. Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus. J Acquir Immune Defic Syndr 2001; 26: 340–344.
  • 209
    Marcellin P, Martinot-Peignoux M, Elias A, Branger M, Courtois F, Level R, et al. Hepatitis C virus (HCV) viremia in human immunodeficiency virus-seronegative and -seropositive patients with indeterminate HCV recombinant immunoblot assay. J Infect Dis 1994; 170: 433–435.
  • 210
    Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33: 562–569.
  • 211
    Sulkowski MS. The HIV-coinfected patient: managing viral hepatitis. J Acquir Immune Defic Syndr 2007; 45 Suppl 2: S36–S37.
  • 212
    Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. Jama 2000; 283: 74–80.
  • 213
    Labarga P, Soriano V, Vispo ME, Pinilla J, Martin-Carbonero L, Castellares C, et al. Hepatotoxicity of Antiretroviral Drugs Is Reduced after Successful Treatment of Chronic Hepatitis C in HIV-Infected Patients. J Infect Dis 2007; 196: 670–676.
  • 214
    Soriano V, Garcia-Samaniego J, Bravo R, Gonzalez J, Castro A, Castilla J, et al. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group. Clin Infect Dis 1996; 23: 585–591.
  • 215
    Laguno M, Murillas J, Blanco JL, Martinez E, Miquel R, Sanchez-Tapias JM, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. Aids 2004; 18: F27–F36.
  • 216
    Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451–459.
  • 217
    Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438–450.
  • 218
    Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. Jama 2004; 292: 2839–2848.
  • 219
    Soriano V, Bravo R, Garcia-Samaniego J, Castilla J, Gonzalez J, Castro A, et al. Relapses of chronic hepatitis C in HIV-infected patients who responded to interferon therapy. Hepatitis/HIV Spanish Study Group. Aids 1997; 11: 400–401.
  • 220
    Mauss S, Valenti W, DePamphilis J, Duff F, Cupelli L, Passe S, et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. Aids 2004; 18: F21–F25.
  • 221
    Moore RD. Human immunodeficiency virus infection, anemia, and survival. Clin Infect Dis 1999; 29: 44–49.
  • 222
    Alvarez D, Dieterich DT, Brau N, Moorehead L, Ball L, Sulkowski MS. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepat 2006; 13: 683–689.
    Direct Link:
  • 223
    Hoggard PG, Kewn S, Barry MG, Khoo SH, Back DJ. Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro. Antimicrob Agents Chemother 1997; 41: 1231–1236.
  • 224
    Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001; 357: 280–281.
  • 225
    Salmon-Ceron D, Chauvelot-Moachon L, Abad S, Silbermann B, Sogni P. Mitochondrial toxic effects and ribavirin. Lancet 2001; 357: 1803–1804.
  • 226
    Bristol Myers Squibb. Patient Information. Packageinserts.bms.com/pi/pi_videx_ec.pdf. 2003.
  • 227
    Zylberberg H, Benhamou Y, Lagneaux JL, Landau A, Chaix ML, Fontaine H, et al. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut 2000; 47: 694–697.
  • 228
    Landau A, Batisse D, Piketty C, Jian R, Kazatchkine MD. Lack of interference between ribavirin and nucleosidic analogues in HIV/HCV co-infected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy. Aids 2000; 14: 1857–1858.
  • 229
    Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996; 24: 38–47.
  • 230
    Lane HC, Davey V, Kovacs JA, Feinberg J, Metcalf JA, Herpin B, et al. Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial. Ann Intern Med 1990; 112: 805–811.
  • 231
    Valerio L, Yazdanpanah Y, Poizot-Martin I, Rosenthal E, Marimoutou C, Gastaut JA, et al. Baseline CD4 cell count and outcome of pegylated interferon plus ribavirin therapy in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2008; 47: 50–55.
  • 232
    Opravil M, Sasadeusz J, Cooper DA, Rockstroh JK, Clumeck N, Clotet B, eta al. Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection. J Acquir Immune Defic Syndr 2008; 47: 36–49.
  • 233
    Roland ME, Havlir DV. Responding to organ failure in HIV-infected patients. N Engl J Med 2003; 348: 2279–2281.
  • 234
    Duclos-Vallee JC, Feray C, Sebagh M, Teicher E, Roque-Afonso AM, Roche B, et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. HEPATOLOGY 2008; 47: 407–417.
    Direct Link:
  • 235
    Fissell RB, Bragg-Gresham JL, Woods JD, Jadoul M, Gillespie B, Hedderwick SA, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2004; 65: 2335–2342.
  • 236
    Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. HEPATOLOGY 2002; 36: 3–10.
    Direct Link:
  • 237
    Tokars JI, Miller ER, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 1997. Semin Dial 2000; 13: 75–85.
    Direct Link:
  • 238
    Saha D, Agarwal SK. Hepatitis and HIV infection during haemodialysis. J Indian Med Assoc 2001; 99: 194–9, 203, 213.
  • 239
    Moreira RC, Lemos MF, Longui CA, Granato C. Hepatitis C and hemodialysis: a review. Braz J Infect Dis 2005; 9: 269–275.
  • 240
    Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep 2001; 50: 1–43.
  • 241
    Tang S, Lai KN. Chronic viral hepatitis in hemodialysis patients. Hemodial Int 2005; 9: 169–179.
    Direct Link:
  • 242
    Jadoul M, Cornu C, van Ypersele de Strihou C. Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian Multicenter Study. The Universitaires Cliniques St-Luc (UCL) Collaborative Group. Kidney Int 1998; 53: 1022–1025.
  • 243
    D'Amico G. Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis. Kidney Int 1998; 54: 650–671.
  • 244
    Sabry AA, Sobh MA, Irving WL, Grabowska A, Wagner BE, Fox S, et al. A comprehensive study of the association between hepatitis C virus and glomerulopathy. Nephrol Dial Transplant 2002; 17: 239–245.
  • 245
    Dore MP, Fattovich G, Sepulveda AR, Realdi G. Cryoglobulinemia related to hepatitis C virus infection. Dig Dis Sci 2007; 52: 897–907.
  • 246
    Roccatello D, Fornasieri A, Giachino O, Rossi D, Beltrame A, Banfi G, et al. Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am J Kidney Dis 2007; 49: 69–82.
  • 247
    Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327: 1490–1495.
  • 248
    Markowitz GS, Cheng JT, Colvin RB, Trebbin WM, D'Agati VD. Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy. J Am Soc Nephrol 1998; 9: 2244–2252.
  • 249
    Marcelli D, Stannard D, Conte F, Held PJ, Locatelli F, Port FK. ESRD patient mortality with adjustment for comorbid conditions in Lombardy (Italy) versus the United States. Kidney Int 1996; 50: 1013–1018.
  • 250
    Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999; 354: 93–99.
  • 251
    Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 2000; 11: 1896–1902.
  • 252
    Lee WC, Shu KH, Cheng CH, Wu MJ, Chen CH, Lian JC. Long-term impact of hepatitis B, C virus infection on renal transplantation. Am J Nephrol 2001; 21: 300–306.
  • 253
    Bruchfeld A, Wilczek H, Elinder CG. Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation. Transplantation 2004; 78: 745–750.
  • 254
    Aroldi A, Lampertico P, Montagnino G, Passerini P, Villa M, Campise MR, et al. Natural history of hepatitis B and C in renal allograft recipients. Transplantation 2005; 79: 1132–1136.
  • 255
    Bloom RD, Rao V, Weng F, Grossman RA, Cohen D, Mange KC. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol 2002; 13: 1374–1380.
  • 256
    Kamar N, Mariat C, Delahousse M, Dantal J, Najjar AA, Cassuto E, et al. Diabetes mellitus after kidney transplantation: a French multicentre observational study. Nephrol Dial Transplant 2007; 22: 1986–1993.
  • 257
    Fabrizi F, Martin P, Dixit V, Bunnapradist S, Kanwal F, Dulai G. Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies. Am J Transplant 2005; 5: 2433–2440.
    Direct Link:
  • 258
    Roth D, Cirocco R, Zucker K, Ruiz P, Viciana A, Burke G, et al. De novo membranoproliferative glomerulonephritis in hepatitis C virus-infected renal allograft recipients. Transplantation 1995; 59: 1676–1682.
  • 259
    Floege J. Recurrent glomerulonephritis following renal transplantation: an update. Nephrol Dial Transplant 2003; 18: 1260–1265.
  • 260
    Choy BY, Chan TM, Lai KN. Recurrent glomerulonephritis after kidney transplantation. Am J Transplant 2006; 6: 2535–2542.
    Direct Link:
  • 261
    Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137–147.
  • 262
    Guh JY, Lai YH, Yang CY, Chen SC, Chuang WL, Hsu TC, et al. Impact of decreased serum transaminase levels on the evaluation of viral hepatitis in hemodialysis patients. Nephron 1995; 69: 459–465.
  • 263
    Fabrizi F, Lunghi G, Finazzi S, Colucci P, Pagano A, Ponticelli C, et al. Decreased serum aminotransferase activity in patients with chronic renal failure: impact on the detection of viral hepatitis. Am J Kidney Dis 2001; 38: 1009–1015.
  • 264
    Perez RM, Ferreira AS, Medina-Pestana JO, Lanzoni VP, Silva AE, Ferraz ML. Is alanine aminotransferase a good marker of histologic hepatic damage in renal transplant patients with hepatitis C virus infection? Clin Transplant 2005; 19: 622–625.
    Direct Link:
  • 265
    Contreras AM, Ruiz I, Polanco-Cruz G, Monteon FJ, Celis A, Vazquez G, et al. End-stage renal disease and hepatitis C infection: comparison of alanine aminotransferase levels and liver histology in patients with and without renal damage. Ann Hepatol 2007; 6: 48–54.
  • 266
    Brophy DF, Martin EJ, Carr SL, Kirschbaum B, Carr ME Jr. The effect of uremia on platelet contractile force, clot elastic modulus and bleeding time in hemodialysis patients. Thromb Res 2007; 119: 723–729.
  • 267
    Kaw D, Malhotra D. Platelet dysfunction and end-stage renal disease. Semin Dial 2006; 19: 317–322.
    Direct Link:
  • 268
    Weigert AL, Schafer AI. Uremic bleeding: pathogenesis and therapy. Am J Med Sci 1998; 316: 94–104.
  • 269
    Lemos LB, Perez RM, Lemos MM, Lanzoni VP, Draibe SA, Silva IS, et al. Hepatitis C in chronic kidney disease: predialysis patients present more severe histological liver injury than hemodialysis patients? Am J Nephrol 2007; 27: 191–196.
  • 270
    Martin P, Carter D, Fabrizi F, Dixit V, Conrad AJ, Artinian L, et al. Histopathological features of hepatitis C in renal transplant candidates [see comment]. Transplantation 2000; 69: 1479–1484.
  • 271
    Furusyo N, Hayashi J, Kanamoto-Tanaka Y, Ariyama I, Etoh Y, Shigematsu M, et al. Liver damage in hemodialysis patients with hepatitis C virus viremia: a prospective 10-year study. Dig Dis Sci 2000; 45: 2221–2228.
  • 272
    Rockey D, Caldwell, AH, Goodman, ZD, Nelson, RC, Smith, AD. AASLD Position Paper: Liver Biopsy. HEPATOLOGY 2009; 49: 1017–1044.
    Direct Link:
  • 273
    Kidney disease: improving global outcomes (KDIGO). Kidney Int Suppl 2008: S1–S99.
  • 274
    Bocci V, Pacini A, Muscettola M, Paulesu L, Pessina GP, Santiano M, et al. Renal filtration, absorption and catabolism of human alpha interferon. J Interferon Res 1981; 1: 347–352.
  • 275
    Bino T, Madar Z, Gertler A, Rosenberg H. The kidney is the main site of interferon degradation. J Interferon Res 1982; 2: 301–308.
  • 276
    Kramer TH, Gaar GG, Ray CG, Minnich L, Copeland JG, Connor JD. Hemodialysis clearance of intravenously administered ribavirin. Antimicrob Agents Chemother 1990; 34: 489–490.
  • 277
    Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis 1999; 19 Suppl 1: 17–24.
  • 278
    Uchihara M, Izumi N, Sakai Y, Yauchi T, Miyake S, Sakai T, et al. Interferon therapy for chronic hepatitis C in hemodialysis patients: increased serum levels of interferon. Nephron 1998; 80: 51–56.
  • 279
    Rostaing L, Chatelut E, Payen JL, Izopet J, Thalamas C, Ton-That H, et al. Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol 1998; 9: 2344–2348.
  • 280
    Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000; 68: 556–567.
  • 281
    Gupta SK, Pittenger AL, Swan SK, Marbury TC, Tobillo E, Batra V, et al. Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction. J Clin Pharmacol 2002; 42: 1109–1115.
  • 282
    Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat 2006; 13: 316–321.
    Direct Link:
  • 283
    Bruchfeld A, Lindahl K, Stahle L, Soderberg M, Schvarcz R. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant 2003; 18: 1573–1580.
  • 284
    Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH. Hepatitis C and renal disease: an update. Am J Kidney Dis 2003; 42: 631–657.
  • 285
    Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 2003; 18: 1071–1081.
    Direct Link:
  • 286
    Russo MW, Goldsweig CD, Jacobson IM, Brown RS Jr. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol 2003; 98: 1610–1615.
    Direct Link:
  • 287
    Rivera M, Gentil MA, Sayago M, Gonzalez Roncero F, Trigo C, Algarra G, et al. Treatment of hepatitis C virus with interferon in hemodialysis patients awaiting kidney transplant. Transplant Proc 2005; 37: 1424–1425.
  • 288
    Rocha CM, Perez RM, Ferreira AP, Carvalho-Filho RJ, Pace FH, Silva IS, et al. Efficacy and tolerance of interferon-alpha in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis. Liver Int 2006; 26: 305–310.
    Direct Link:
  • 289
    Kalia H, Lopez PM, Martin P. Treatment of HCV in patients with renal failure. Arch Med Res 2007; 38: 628–633.
  • 290
    Tan AC, Brouwer JT, Glue P, van Leusen R, Kauffmann RH, Schalm SW, et al. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study. Nephrol Dial Transplant 2001; 16: 193–195.
  • 291
    Mousa DH, Abdalla AH, Al-Shoail G, Al-Sulaiman MH, Al-Hawas FA, Al-Khader AA. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant Proc 2004; 36: 1831–1834.
  • 292
    Chan TM, Ho SK, Tang CS, Tse KC, Lam MF, Lai KN, et al. Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection. Nephrology (Carlton) 2007; 12: 11–17.
    Direct Link:
  • 293
    Sporea I, Popescu A, Sirli R, Golea O, Totolici C, Danila M, et al. Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis. World J Gastroenterol 2006; 12: 4191–4194.
  • 294
    Kokoglu OF, Ucmak H, Hosoglu S, Cetinkaya A, Kantarceken B, Buyukbese MA, et al. Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. J Gastroenterol Hepatol 2006; 21: 575–580.
    Direct Link:
  • 295
    Covic A, Maftei ID, Mardare NG, Ionita-Radu F, Totolici C, Tuta L, et al. Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit. J Nephrol 2006; 19: 794–801.
  • 296
    Russo MW, Ghalib R, Sigal S, Joshi V. Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 2006; 21: 437–443.
  • 297
    Rendina M, Schena A, Castellaneta NM, Losito F, Amoruso AC, Stallone G, et al. The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol 2007; 46: 768–774.
  • 298
    Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725–1730.
  • 299
    Campistol JM, Esforzado N, Martinez J, Rosello L, Veciana L, Modol J, et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrol Dial Transplant 1999; 14: 2704–2709.
  • 300
    Carriero D, Fabrizi F, Uriel AJ, Park J, Martin P, Dieterich DT. Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin. Int J Artif Organs 2008; 31: 295–302.
  • 301
    Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 1995; 59: 1426–1431.
  • 302
    Tang S, Cheng IK, Leung VK, Kuok UI, Tang AW, Wing Ho Y, et al. Successful treatment of hepatitis C after kidney transplantation with combined interferon alpha-2b and ribavirin. J Hepatol 2003; 39: 875–878.
  • 303
    Shu KH, Lan JL, Wu MJ, Cheng CH, Chen CH, Lee WC, et al. Ultralow-dose alpha-interferon plus ribavirin for the treatment of active hepatitis C in renal transplant recipients. Transplantation 2004; 77: 1894–1896.
  • 304
    Sharma RK, Bansal SB, Gupta A, Gulati S, Kumar A, Prasad N. Chronic hepatitis C virus infection in renal transplant: treatment and outcome. Clin Transplant 2006; 20: 677–683.
    Direct Link:
  • 305
    Fontaine H, Vallet-Pichard A, Equi-Andrade C, Nalpas B, Verkarre V, Chaix ML, et al. Histopathologic efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis C. Transplantation 2004; 78: 853–857.
  • 306
    Kamar N, Ribes D, Izopet J, Rostaing L. Treatment of hepatitis C virus infection (HCV) after renal transplantation: implications for HCV-positive dialysis patients awaiting a kidney transplant. Transplantation 2006; 82: 853–856.
  • 307
    Toth CM, Pascual M, Chung RT, Graeme-Cook F, Dienstag JL, Bhan AK, et al. Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: response to interferon-alpha therapy. Transplantation 1998; 66: 1254–1258.
  • 308
    Cid MC, Hernandez-Rodriguez J, Robert J, del Rio A, Casademont J, Coll-Vinent B, et al. Interferon-alpha may exacerbate cryoblobulinemia-related ischemic manifestations: an adverse effect potentially related to its anti-angiogenic activity. Arthritis Rheum 1999; 42: 1051–1055.
    Direct Link:
  • 309
    Suzuki T, Yonemura K, Miyaji T, Suzuki H, Takahira R, Fujigaki Y, et al. Progressive renal failure and blindness due to retinal hemorrhage after interferon therapy for hepatitis C virus-associated membranoproliferative glomerulonephritis. Intern Med 2001; 40: 708–712.
  • 310
    Kamar N, Rostaing L, Alric L. Treatment of hepatitis C-virus-related glomerulonephritis. Kidney Int 2006; 69: 436–439.
  • 311
    Basse G, Ribes D, Kamar N, Mehrenberger M, Esposito L, Guitard J, et al. Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients. Transplantation 2005; 80: 1560–1564.
  • 312
    Garini G, Allegri L, Vaglio A, Buzio C. Hepatitis C virus-related cryoglobulinemia and glomerulonephritis: pathogenesis and therapeutic strategies. Ann Ital Med Int 2005; 20: 71–80.
  • 313
    Misiani R, Bellavita P, Fenili D, Vicari O, Marchesi D, Sironi PL, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994; 330: 751–756.
  • 314
    Cresta P, Musset L, Cacoub P, Frangeul L, Vitour D, Poynard T, et al. Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus. Gut 1999; 45: 122–128.
  • 315
    Garini G, Allegri L, Carnevali L, Catellani W, Manganelli P, Buzio C. Interferon-alpha in combination with ribavirin as initial treatment for hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis. Am J Kidney Dis 2001; 38: E35.
  • 316
    Rossi P, Bertani T, Baio P, Caldara R, Luliri P, Tengattini F, et al. Hepatitis C virus-related cryoglobulinemic glomerulonephritis: long-term remission after antiviral therapy. Kidney Int 2003; 63: 2236–2241.
  • 317
    Mazzaro C, Zorat F, Caizzi M, Donada C, Di Gennaro G, Maso LD, et al. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol 2005; 42: 632–638.
  • 318
    Cacoub P, Saadoun D, Limal N, Sene D, Lidove O, Piette JC. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 2005; 52: 911–915.
    Direct Link:
  • 319
    Saadoun D, Resche-Rigon M, Thibault V, Piette JC, Cacoub P. Antiviral therapy for hepatitis C virus–associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum 2006; 54: 3696–706.
    Direct Link:
  • 320
    El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004; 127: S27–S34.
  • 321
    Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350: 2265–2271.
  • 322
    Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131: 470–477.
  • 323
    Jacobson IM, Brown RS Jr, McCone J, Black M, Albert C, Dragutsky MS, et al. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. HEPATOLOGY 2007; 46: 982–990.
    Direct Link:
  • 324
    Shiffman ML, Mihas AA, Millwala F, Sterling RK, Luketic VA, Stravitz RT, et al. Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3. Am J Gastroenterol 2007; 102: 761–766.
    Direct Link:
  • 325
    Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. HEPATOLOGY 2004; 39: 1702–1708.
    Direct Link:
  • 326
    Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673–1680.
  • 327
    Helbling B, Jochum W, Stamenic I, Knopfli M, Cerny A, Borovicka J, et al. HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin. J Viral Hepat 2006; 13: 762–769.
    Direct Link:
  • 328
    Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32: 673–684.
  • 329
    Sanchez-Fueyo A, Restrepo JC, Quinto L, Bruguera M, Grande L, Sanchez-Tapias JM, et al. Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation 2002; 73: 56–63.
  • 330
    Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8: 350–355.
    Direct Link:
  • 331
    Forns X, Garcia-Retortillo M, Serrano T, Feliu A, Suarez F, de la Mata M, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39: 389–396.
  • 332
    Thomas RM, Brems JJ, Guzman-Hartman G, Yong S, Cavaliere P, Van Thiel DH. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 2003; 9: 905–915.
    Direct Link:
  • 333
    Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. HEPATOLOGY 2005; 42: 255–262.
    Direct Link:
  • 334
    Iacobellis A, Siciliano M, Perri F, Annicchiarico BE, Leandro G, Caruso N, et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 2007; 46: 206–212.
  • 335
    Wright TL, Donegan E, Hsu HH, Ferrell L, Lake JR, Kim M, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992; 103: 317–322.
  • 336
    Pereira BJ, Natov SN, Bouthot BA, Murthy BV, Ruthazer R, Schmid CH, et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int 1998; 53: 1374–1381.
  • 337
    Gudmundsson GS, Malinowska K, Robinson JA, Pisani BA, Mendez JC, Foy BK, et al. Five-year follow-up of hepatitis C-naive heart transplant recipients who received hepatitis C-positive donor hearts. Transplant Proc 2003; 35: 1536–1538.
  • 338
    Lunel F, Cadranel JF, Rosenheim M, Dorent R, Di-Martino V, Payan C, et al. Hepatitis virus infections in heart transplant recipients: epidemiology, natural history, characteristics, and impact on survival. Gastroenterology 2000; 119: 1064–1074.
  • 339
    Marelli D, Bresson J, Laks H, Kubak B, Fonarow G, Tsai FC, et al. Hepatitis C-positive donors in heart transplantation. Am J Transplant 2002; 2: 443–447.
    Direct Link:
  • 340
    Haji SA, Starling RC, Avery RK, Mawhorter S, Tuzcu EM, Schoenhagen P, et al. Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation. J Heart Lung Transplant 2004; 23: 277–283.
  • 341
    Sahi H, Zein NN, Mehta AC, Blazey HC, Meyer KH, Budev M. Outcomes after lung transplantation in patients with chronic hepatitis C virus infection. J Heart Lung Transplant 2007; 26: 466–471.
  • 342
    Fagiuoli S, Cooper DK, Zuhdi N. Hepatitis C status of heart transplant recipients. Clin Transplant 1998; 12: 5–10.
  • 343
    Doucette KE, Weinkauf J, Sumner S, Ens K, Lien D. Treatment of hepatitis C in potential lung transplant candidates. Transplantation 2007; 83: 1652–1655.
  • 344
    Ghobrial RM, Steadman R, Gornbein J, Lassman C, Holt CD, Chen P, et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg 2001; 234: 384–393; discussion 393–394.
  • 345
    Neumann UP, Berg T, Bahra M, Puhl G, Guckelberger O, Langrehr JM, et al. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation 2004; 77: 226–231.
  • 346
    Neumann UP, Berg T, Bahra M, Seehofer D, Langrehr JM, Neuhaus R, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41: 830–836.
  • 347
    Yilmaz N, Shiffman ML, Stravitz RT, Sterling RK, Luketic VA, Sanyal AJ, et al. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl 2007; 13: 975–983.
    Direct Link:
  • 348
    Rowe IA, Webb K, Gunson BK, Mehta N, Haque S, Neuberger J. The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl Int 2008; 21: 459–465.
    Direct Link:
  • 349
    Sheiner PA, Boros P, Klion FM, Thung SN, Schluger LK, Lau JY, et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. HEPATOLOGY 1998; 28: 831–838.
    Direct Link:
  • 350
    Singh N, Gayowski T, Wannstedt CF, Shakil AO, Wagener MM, Fung JJ, et al. Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial. Transplantation 1998; 65: 82–86.
  • 351
    Chalasani N, Manzarbeitia C, Ferenci P, Vogel W, Fontana RJ, Voigt M, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. HEPATOLOGY 2005; 41: 289–298.
    Direct Link:
  • 352
    Mazzaferro V, Tagger A, Schiavo M, Regalia E, Pulvirenti A, Ribero ML, et al. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transplant Proc 2001; 33: 1355–1357.
  • 353
    Sugawara Y, Makuuchi M, Matsui Y, Kishi Y, Akamatsu N, Kaneko J, et al. Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation 2004; 78: 1308–1311.
  • 354
    Gane EJ, Lo SK, Riordan SM, Portmann BC, Lau JY, Naoumov NV, et al. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. HEPATOLOGY 1998; 27: 1403–1407.
    Direct Link:
  • 355
    Firpi RJ, Abdelmalek MF, Soldevila-Pico C, Reed A, Hemming A, Howard R, et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002; 8: 1000–1006.
    Direct Link:
  • 356
    Samuel D, Bizollon T, Feray C, Roche B, Ahmed SN, Lemonnier C, et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003; 124: 642–650.
  • 357
    Bizollon T, Ahmed SN, Radenne S, Chevallier M, Chevallier P, Parvaz P, et al. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut 2003; 52: 283–287.
  • 358
    Berenguer M, Palau A, Fernandez A, Benlloch S, Aguilera V, Prieto M, et al. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006; 12: 1067–1076.
    Direct Link:
  • 359
    Berenguer M, Prieto M, Palau A, Carrasco D, Rayon JM, Calvo F, et al. Recurrent hepatitis C genotype 1b following liver transplantation: treatment with combination interferon-ribavirin therapy. Eur J Gastroenterol Hepatol 2004; 16: 1207–1212.
  • 360
    Mukherjee S, Lyden E, McCashland TM, Schafer DF. Interferon alpha 2b and ribavirin for the treatment of recurrent hepatitis C after liver transplantation: cohort study of 38 patients. J Gastroenterol Hepatol 2005; 20: 198–203.
    Direct Link:
  • 361
    Mukherjee S. Pegylated interferon alfa-2a and ribavirin for recurrent hepatitis C after liver transplantation. Transplant Proc 2005; 37: 4403–4405.
  • 362
    Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004; 40: 669–674.
  • 363
    Castells L, Vargas V, Allende H, Bilbao I, Luis Lazaro J, Margarit C, et al. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005; 43: 53–59.
  • 364
    Neumann U, Puhl G, Bahra M, Berg T, Langrehr JM, Neuhaus R, et al. Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin. Transplantation 2006; 82: 43–7.
  • 365
    Oton E, Barcena R, Moreno-Planas JM, Cuervas-Mons V, Moreno-Zamora A, Barrios C, et al. Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin. Am J Transplant 2006; 6: 2348–1255.
    Direct Link:
  • 366
    Sharma P, Marrero JA, Fontana RJ, Greenson JK, Conjeevaram H, Su GL, et al. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl 2007; 13: 1100–1108.
    Direct Link:
  • 367
    Samuel D, Forns X, Berenguer M, Trautwein C, Burroughs A, Rizzetto M, et al. Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). J Hepatol 2006; 45: 127–143.
  • 368
    Angelico M, Petrolati A, Lionetti R, Lenci I, Burra P, Donato MF, et al. A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol 2007; 46: 1009–1017.
  • 369
    Carrion JA, Navasa M, Garcia-Retortillo M, Garcia-Pagan JC, Crespo G, Bruguera M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007; 132: 1746–1756.
  • 370
    Firpi RJ, Zhu H, Morelli G, Abdelmalek MF, Soldevila-Pico C, Machicao VI, et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl 2006; 12: 51–57.
    Direct Link:
  • 371
    Stravitz RT, Shiffman ML, Sanyal AJ, Luketic VA, Sterling RK, Heuman DM, et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl 2004; 10: 850–858.
    Direct Link:
  • 372
    Saab S, Kalmaz D, Gajjar NA, Hiatt J, Durazo F, Han S, et al. Outcomes of acute rejection after interferon therapy in liver transplant recipients. Liver Transpl 2004; 10: 859–867.
    Direct Link:
  • 373
    Biselli M, Andreone P, Gramenzi A, Lorenzini S, Loggi E, Bonvicini F, et al. Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naive and non-responder patients on a stable immunosuppressive regimen. Dig Liver Dis 2006; 38: 27–32.
  • 374
    Oton E, Barcena R, Garcia-Garzon S, Moreno-Zamora A, Moreno A, Garcia-Gonzalez M, et al. Pegylated interferon and ribavirin for the recurrence of chronic hepatitis C genotype 1 in transplant patients. Transplant Proc 2005; 37: 3963–3964.
  • 375
    Berenguer M, Prieto M, Rayon JM, Mora J, Pastor M, Ortiz V, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. HEPATOLOGY 2000; 32: 852–858.
    Direct Link:
  • 376
    Bahra M, Neumann UP, Jacob D, Berg T, Neuhaus R, Langrehr JM, et al. Outcome after liver re-transplantation in patients with recurrent chronic hepatitis C. Transpl Int 2007; 20: 771–778.
    Direct Link:
  • 377
    Rosen HR, Martin P. Hepatitis C infection in patients undergoing liver retransplantation. Transplantation 1998; 66: 1612–1616.
  • 378
    Vogel W, Graziadei I, Umlauft F, Datz C, Hackl F, Allinger S, et al. High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: a pilot study. Dig Dis Sci 1996; 41: 81S–85S.
  • 379
    Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345: 1452–1457.
  • 380
    Licata A, Di Bona D, Schepis F, Shahied L, Craxi A, Camma C. When and how to treat acute hepatitis C? J Hepatol 2003; 39: 1056–1062.
  • 381
    Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125: 80–88.
  • 382
    Kamal SM, Fouly AE, Kamel RR, Hockenjos B, Al Tawil A, Khalifa KE, et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 2006; 130: 632–638.
  • 383
    Nomura H, Sou S, Tanimoto H, Nagahama T, Kimura Y, Hayashi J, et al. Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial. HEPATOLOGY 2004; 39: 1213–129.
    Direct Link:
  • 384
    De Rosa FG, Bargiacchi O, Audagnotto S, Garazzino S, Cariti G, Raiteri R, et al. Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C. J Antimicrob Chemother 2006; 57: 360–363.
  • 385
    Calleri G, Cariti G, Gaiottino F, De Rosa FG, Bargiacchi O, Audagnotto S, et al. A short course of pegylated interferon-alpha in acute HCV hepatitis. J Viral Hepat 2007; 14: 116–121.
    Direct Link:
  • 386
    Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. HEPATOLOGY 1999; 29: 908–914.
    Direct Link:
  • 387
    Cox AL, Netski DM, Mosbruger T, Sherman SG, Strathdee S, Ompad D, et al. Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis 2005; 40: 951–958.
  • 388
    Hoofnagle JH. Course and outcome of hepatitis C. HEPATOLOGY 2002; 36(Suppl): S21–S29.
    Direct Link:
  • 389
    Edlin BR, Seal KH, Lorvick J, Kral AH, Ciccarone DH, Moore LD, et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med 2001; 345: 211–215.
  • 390
    Gossop M, Marsden J, Stewart D, Rolfe A. Patterns of improvement after methadone treatment: 1 year follow-up results from the National Treatment Outcome Research Study. Drug Alcohol Depend 2000; 60: 275–286.
  • 391
    Geber WF, Lefkowitz SS, Hung CY. Effect of morphine, hydromorphone, methadone, mescaline, trypan blue, vitamin A, sodium salicylate, and caffeine on the serum interferon level in response to viral infection. Arch Int Pharmacodyn Ther 1975; 214: 322–327.
  • 392
    Sylvestre DL. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002; 67: 117–123.
  • 393
    Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. HEPATOLOGY 2003; 37: 443–451.
    Direct Link:
  • 394
    Mehta SH, Cox A, Hoover DR, Wang XH, Mao Q, Ray S, et al. Protection against persistence of hepatitis C. Lancet 2002; 359: 1478–1483.
  • 395
    Farci P, Alter HJ, Govindarajan S, Wong DC, Engle R, Lesniewski RR, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992; 258: 135–140.
  • 396
    Backmund M, Meyer K, Edlin BR. Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis 2004; 39: 1540–1543.
  • 397
    Golub ET, Latka M, Hagan H, Havens JR, Hudson SM, Kapadia F, et al. Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck Depression Inventory. J Urban Health 2004; 81: 278–290.
  • 398
    Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. HEPATOLOGY 2001; 34: 188–193.
    Direct Link:
  • 399
    Matthews G, Kronborg IJ, Dore GJ. Treatment for hepatitis C virus infection among current injection drug users in Australia. Clin Infect Dis 2005; 40(Suppl 5): S325–S329.
  • 400
    Stein MD, Maksad J, Clarke J. Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. Drug Alcohol Depend 2001; 61: 211–215.
  • 401
    Sylvestre DL, Litwin AH, Clements BJ, Gourevitch MN. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. J Subst Abuse Treat 2005; 29: 159–165.
  • 402
    Renault PF, Hoofnagle JH, Park Y, Mullen KD, Peters M, Jones DB, et al. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 1987; 147: 1577–1580.
  • 403
    Schaefer M, Hinzpeter A, Mohmand A, Janssen G, Pich M, Schwaiger M, et al. Hepatitis C treatment in “difficult-to-treat” psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. HEPATOLOGY 2007; 46: 991–998.
    Direct Link:
  • 404
    Wiley TE, McCarthy M, Breidi L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. HEPATOLOGY 1998; 28: 805–809.
    Direct Link:
  • 405
    Corrao G, Arico S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. HEPATOLOGY 1998; 27: 914–919.
    Direct Link:
  • 406
    Bellentani S, Pozzato G, Saccoccio G, Crovatto M, Croce LS, Mazzoran L, et al. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut 1999; 44: 874–880.
  • 407
    Noda K, Yoshihara H, Suzuki K, Yamada Y, Kasahara A, Hayashi N, et al. Progression of type C chronic hepatitis to liver cirrhosis and hepatocellular carcinoma—its relationship to alcohol drinking and the age of transfusion. Alcohol Clin Exp Res 1996; 20: 95A–100A.
    Direct Link:
  • 408
    Pessione F, Degos F, Marcellin P, Duchatelle V, Njapoum C, Martinot-Peignoux M, et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. HEPATOLOGY 1998; 27: 1717–1722.
    Direct Link:
  • 409
    Romero-Gomez M, Grande L, Nogales MC, Fernandez M, Chavez M, Castro M. Intrahepatic hepatitis C virus replication is increased in patients with regular alcohol consumption. Dig Liver Dis 2001; 33: 698–702.
  • 410
    Westin J, Lagging LM, Spak F, Aires N, Svensson E, Lindh M, et al. Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection. J Viral Hepat 2002; 9: 235–2341.
    Direct Link:
  • 411
    Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. HEPATOLOGY 1999; 29: 1215–1219.
    Direct Link:
  • 412
    Ortiz V, Berenguer M, Rayon JM, Carrasco D, Berenguer J. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 2002; 97: 2408–2414.
    Direct Link:
  • 413
    Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338: 286–290.
  • 414
    Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999; 48: 1–37.
  • 415
    Tsai JF, Jeng JE, Ho MS, Chang WY, Lin ZY, Tsai JH. Independent and additive effect modification of hepatitis C and B viruses infection on the development of chronic hepatitis. J Hepatol 1996; 24: 271–276.
  • 416
    Seeff LB, Lindsay KL, Bacon BR, Kresina TF, Hoofnagle JH. Complementary and alternative medicine in chronic liver disease. HEPATOLOGY 2001; 34: 595–603.
    Direct Link:
  • 417
    Strader DB, Bacon BR, Lindsay KL, La Brecque DR, Morgan T, Wright EC, et al. Use of complementary and alternative medicine in patients with liver disease. Am J Gastroenterol 2002; 97: 2391–2397.
    Direct Link:
  • 418
    Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky HL, Dienstag JL, et al. Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. HEPATOLOGY 2008; 47: 605–612.
    Direct Link:
  • 419
    Seeff LB. Herbal hepatotoxicity. Clin Liver Dis 2007; 11: 577–596, vii.
View Full Article with Supporting Information (HTML) Get PDF (444K)